Research programme: anti-infectives - Transave

Drug Profile

Research programme: anti-infectives - Transave

Alternative Names: Anti-infectives research programme - Transave; SLIT™ TR04; TR 04

Latest Information Update: 19 Mar 2011

Price : $50

At a glance

  • Originator Transave
  • Developer Insmed
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 02 Dec 2010 Transave has been acquired and merged into Insmed
  • 22 Jun 2005 This programme is still in active development - (BIO-2005)
  • 13 Jul 2004 Preclinical trials in Anthrax in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top